IL-6 tertile | |||
---|---|---|---|
Low | Medium | High | |
Adalimumab 40 mg q2w, n (%) | 45 (30) | 53 (35) | 54 (35) |
Sarilumab 200 mg q2w, n (%) | 55 (37) | 47 (32) | 46 (31) |
CRP (mg/L) mean (± SD) [range]* | 5.62 (9.18) | 15.24 (17.14) | 41.51 (34.14) |
[0.2–48.2] | [1.0–120.0] | [2.2–202.0] | |
ESR (mm/h) mean (± SD) [range]* | 38.99 (15.56) | 44.96 (20.35) | 59.02 (26.48) |
[7.0–104.0] | [14.0–130.0] | [4.0–130.0] | |
Positive RF (> 15 IU/mL), n (%)** | 46 (46) | 72 (74) | 73 (73) |
Postive ACPA (≥ 17 U/mL), n (%)** | 53 (55) | 78 (81) | 87 (87) |
IL-6, pg/mL, median [range] | 2.4 [1.6–7.1] | 16.2 [7.2–39.5] | 64.7 [39.6–692.3] |
Baseline HRQoL scores, mean (± SD) [range] | |||
SF-36 summary scores (0–100) | |||
PCS | 31.78 (6.16) | 30.96 (6.25) | 30.36 (6.56) |
[16.5–46.0] | [18.4–47.5] | [18.1–52.0] | |
MCS* | 37.49 (10.47) | 38.80 (12.02) | 34.98 (12.61) |
[12.8–61.6] | [11.4–67.1] | [13.1–66.8] | |
SF-36 domain scores (0–100) | |||
PF | 37.02 (20.01) | 35.36 (19.10) | 31.74 (22.36) |
[0.0–85.0] | [0.0–90.0] | [0.0–94.4] | |
RP* | 37.56 (18.74) | 35.75 (19.69) | 30.44 (19.58) |
[0.0–81.3] | [0.0–100.0] | [0.0–87.5] | |
BP* | 31.14 (15.25) | 27.83 (14.42) | 24.63 (16.92) |
[0.0–84.0] | [0.0–70.0] | [0.0–74.0] | |
GH | 33.85 (15.84) | 36.75 (14.78) | 35.77 (17.54) |
[0.0–77.0] | [0.0–82.0] | [0.0–82.0] | |
VT | 34.50 (16.87) | 35.63 (18.04) | 31.94 (17.27) |
[0.0–75.0] | [0.0–87.5] | [0.0–68.8] | |
SF* | 48.99 (22.49) | 50.63 (25.59) | 41.00 (26.77) |
[0.0–100.0] | [0.0–100.0] | [0.0–100.0] | |
RE* | 50.59 (24.26) | 51.92 (26.51) | 42.67 (28.70) |
[0.0–100.0] | [0.0–100.0] | [0.0–100.0] | |
MH | 50.20 (17.95) | 51.80 (20.18) | 47.68 (21.00) |
[10.0–95.0] | [5.0–100.0] | [5.0–100.0] | |
AM-stiffness VAS (0–100 mm)* | 64.60 (19.89) | 68.01 (19.70) | 75.17 (20.33) |
[11.0–100.0] | [10.0–100.0] | [16.0–100.0] | |
FACIT-fatigue (0–52) | 24.12 (9.77) | 24.86 (9.80) | 21.89 (9.62) |
[3.0–50.0] | [1.0–48.0] | [2.0–45.0] |